Analyst consensus rating
Capricor Therapeutics Analyst Rating: Hold
CAPR is rated Hold by 4 analysts with a $10.50 target. As of 2026-08-22.
Direct answer
Capricor Therapeutics's consensus rating is Hold.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.50.
Forecast evidence checked August 22, 2026.
Get free Capricor Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.29
- Average price target
- $10.50
- High price target
- $28.00
- Low price target
- $2.00
- Low target gap
- -68.2%
- Target upside
- +66.9%
- High target gap
- +345.2%
- Target range width
- 413.4%
- Consensus rating
- Hold
- Analysts
- 4
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Capricor Therapeutics?
Capricor Therapeutics has a verified Hold consensus. The same dataset has an average price target of $10.50.
How far are Capricor Therapeutics's low and high targets from the recorded price?
The low target implies -68.2%, while the high target implies +345.2%.
How many analysts are included in Capricor Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Capricor Therapeutics's target upside or downside calculated?
The average target of $10.50 is divided by the recorded price of $6.29, then one is subtracted to produce +66.9%. This does not guarantee a future return.
When was Capricor Therapeutics's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.